From: Clinical and microbiologic characteristics of tcdA-negative variant clostridium difficile infections
A+B+ (n = 101) | A-B+ (n = 21) | P value a | ||
---|---|---|---|---|
Medication | ||||
PPI | N (%) | 35 (34.7) | 6 (28.6) | 0.800 |
H2 blockers | N (%) | 49 (48.5) | 8 (38.1) | 0.474 |
Probiotics | N (%) | 49 (48.5) | 13 (61.9) | 0.339 |
Steroids | N (%) | 37 (36.6) | 7 (33.3) | 1.000 |
Chemotherapy | N (%) | 12 (11.9) | 3 (14.3) | 0.722 |
Antibiotics | ||||
All-DDD | Mean (SD) | 25.4 (18.91) | 27.0 (21.83) | 0.989 |
Days of antibiotic use | Mean (SD) | 18.7 (12.25) | 16.6 (12.23) | 0.317 |
Antibiotics use | ||||
Fluoroquinolones | N (%) | 46 (45.5) | 14 (66.7) | 0.096 |
2nd Quinolones | N (%) | 22 (21.8) | 8 (38.1) | 0.161 |
3rd Quinolones | N (%) | 34 (33.7) | 9 (42.9) | 0.458 |
Clindamycin | N (%) | 17 (16.8) | 11 (52.4) | 0.001 |
ESC | N (%) | 57 (56.4) | 11 (52.4) | 0.811 |
BL/BLI | N (%) | 36 (35.6) | 6 (28.6) | 0.620 |
Carbapenem | N (%) | 10 (9.9) | 2 (9.5) | 1.000 |
Glycopeptides | N (%) | 20 (19.8) | 2 (9.5) | 0.360 |
Metronidazole | N (%) | 29 (28.7) | 3 (14.3) | 0.275 |
Antibiotics dose | ||||
Fluoroquinolones | Mean (SD) | 5.606 (9.2145) | 7.138 (10.0394) | 0.202 |
2nd Quinolones | Mean (SD) | 1.858 (5.1504) | 2.210 (4.7322) | 0.168 |
3rd Quinolones | Mean (SD) | 3.737 (7.2372) | 4.929 (9.3117) | 0.484 |
Clindamycin | Mean (SD) | 1.111 (3.1081) | 4.302 (5.1853) | <0.0001 |
ESC | Mean (SD) | 5.260 (7.7728) | 3.595 (4.5188) | 0.611 |
BL/BLI | Mean (SD) | 3.825 (9.2440) | 3.536 (8.2533) | 0.611 |
Carbapenem | Mean (SD) | 0.636 (3.3368) | 0.524 (1.7210) | 0.995 |
Glycopeptides | Mean (SD) | 1.255 (3.4253) | 0.548 (1.9359) | 0.270 |
Metronidazole | Mean (SD) | 2.850 (6.9772) | 1.397 (3.7901) | 0.194 |